Apthera's longer-term product development goals are aimed at combining NeuVax with Herceptin in the treatment of tumors that over-express HER2/neu. In recent experiments, NeuVax has shown measurable anti-tumor synergy when used after Herceptin in animal models and the combination is now in Phase I/II clinical trials.

Contact us to request more information about our NeuVax + Herceptin clinical program.